Reply

Neil Mehta¹, Francis Y Yao^{1

2}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
² Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA.

Comment

Neil Mehta et al. Hepatology. 2020 Dec.

. 2020 Dec;72(6):2243-2244.

doi: 10.1002/hep.31431.

Neil Mehta¹, Francis Y Yao^{1

2}

¹ Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
² Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA.

No abstract available

Comment on

Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Mehta N, et al. Hepatology. 2019 Mar;69(3):1193-1205. doi: 10.1002/hep.30413. Epub 2019 Feb 10. Hepatology. 2019. PMID: 30548884 Free PMC article.
Letter to the Editor: Comment on Alpha-Fetoprotein Decrease From >1,000 to <500 ng/mL in Patients With Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
Akbulut S, Sahin TT, Yilmaz S. Akbulut S, et al. Hepatology. 2020 Dec;72(6):2242-2243. doi: 10.1002/hep.31433. Hepatology. 2020. PMID: 32583464 No abstract available.

1. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-fetoprotein decrease from >1,000 to <500 ng/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes. Hepatology 2019;69:1193-1205.
1. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. 2016. https://optn.transplant.hrsa.gov/media/1922/liver_hcc_criteria_for_auto_.... Accessed June 13, 2020.
1. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, et al. Wait time <6 and >18 months predicts hepatocellular carcinoma recurrence after liver transplantation. Transplantation 2017;101:2071-2078.
1. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Unfair advantages for hepatocellular carcinoma patients listed for liver transplant in short-wait regions following 2015 policy change. Liver Transpl 2020;26:662-672.